| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/JNNP.34.6.682 |
| P953 | full work available at URL | https://jnnp.bmj.com/content/jnnp/34/6/682.full.pdf |
| https://europepmc.org/articles/PMC1083502 | ||
| https://europepmc.org/articles/PMC1083502?pdf=render | ||
| https://syndication.highwire.org/content/doi/10.1136/jnnp.34.6.682 | ||
| P932 | PMC publication ID | 1083502 |
| P698 | PubMed publication ID | 5158783 |
| P5875 | ResearchGate publication ID | 18009636 |
| P2093 | author name string | H. L. Klawans | |
| S. P. Ringel | |||
| D. M. Shenker | |||
| P2860 | cites work | Aromatic L-amino acid decarboxylase | Q27863457 |
| Genetic regulatory mechanisms in the synthesis of proteins | Q28186173 | ||
| Parkinsonism: onset, progression, and mortality | Q28259134 | ||
| Allosteric proteins and cellular control systems | Q33970893 | ||
| Treatment of Parkinsonism With Levodopa | Q34240368 | ||
| Failure of pyridoxine to reduce drug-induced dyskinesias | Q37070746 | ||
| Impairment of pyridoxal phosphate dependent metabolic reactions in a child with subacute necrotizing encephalopathy | Q37136626 | ||
| Theoretical implications of the use of L-dopa in parkinsonism. A review | Q39893459 | ||
| The pharmacology of parkinsonism (a review). | Q39905086 | ||
| Dopamine (3-hydroxytyramine) and brain function | Q40035585 | ||
| Modification of Parkinsonism--chronic treatment with L-dopa | Q45300970 | ||
| A pharmacologic analysis of Huntington's chorea | Q45301953 | ||
| Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase | Q51208477 | ||
| Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans. | Q51219060 | ||
| On the origin of homovanillic acid in the cerebrospinal fluid. | Q51229138 | ||
| The localization of monoaminergic blood-brain barrier mechanisms | Q51238567 | ||
| L-dopa and cerebrospinal fluid homovanillic acid in parkinsonism | Q67213491 | ||
| Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02) | Q67215088 | ||
| Pyridoxine reversal of L-dopa effects in Parkinsonism. | Q67215488 | ||
| A method for evaluating disability in patients with Parkinson's disease. | Q67225236 | ||
| The action of pyridoxine in primary hyperoxaluria | Q71257156 | ||
| Cerebrospinal fluid 5-hydroxyindoles and behavior after l-tryptophan and pyridoxine administration to psychiatric patients | Q71635180 | ||
| Dopa decarboxylase: substrates, coenzyme, inhibitors | Q72761803 | ||
| [On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6] | Q79210345 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin B6 | Q205130 |
| surgery | Q40821 | ||
| pyridoxine | Q423746 | ||
| P304 | page(s) | 682-686 | |
| P577 | publication date | 1971-12-01 | |
| P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
| P1476 | title | Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor | |
| P478 | volume | 34 |
| Q37397418 | A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency |
| Q64874042 | A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone |
| Q40214373 | Anti-parkinsonian drugs today |
| Q36816763 | High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature |
| Q34075760 | L-Dopa and the Treatment of Extrapyramidal Disease |
| Q53729853 | L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease. |
| Q40575022 | Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism |
| Q37594078 | Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease |
| Q46698198 | Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy |
Search more.